Literature DB >> 22579530

Association of the DDAH2 gene polymorphism with type 2 diabetes and hypertension.

Hyun-Ae Seo1, Su-Won Kim, Eon-Ju Jeon, Ji-Yun Jeong, Seong-Su Moon, Won-Kee Lee, Jung-Guk Kim, In-Kyu Lee, Keun-Gyu Park.   

Abstract

AIMS: The aim of this study was to investigate whether the polymorphism of DDAH2 is associated with type 2 diabetes and hypertension in Korean population.
METHODS: Total 605 subjects were included in this study: 403 patients with type 2 diabetes and 202 non-diabetic control subjects. The SNP rs805304 and rs2272592 in DDAH2 were analyzed. We examined the association of SNP rs805304 and rs2272592 in DDAH2 with type 2 diabetes and hypertension.
RESULTS: SNP rs2272592 was significantly associated with type 2 diabetes (P<0.001) while SNP rs805304 was not (P=0.716). We observed that the prevalence of the AG+GG genotypes were significantly greater than AA homozygotes in type 2 diabetes (AA vs AG+GG; OR 20.74, 95% CI 6.48-66.35, P<0.001). Significance was maintained after adjusting for age, sex, BMI, DBP and BUN (OR 21.03, 95% CI 2.83-151.14, P=0.003). Both SNP rs805304 and rs2272592 in DDAH2 were not significantly associated with hypertension.
CONCLUSIONS: In the present study, we found that SNP rs2272592 in DDAH2 is associated with type 2 diabetes but SNP rs805304 in DDAH2 is not. DDAH2 SNP rs2272592 AG+GG genotypes are associated with genetic susceptibility to type 2 diabetes in Korean population.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22579530     DOI: 10.1016/j.diabres.2012.04.015

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  5 in total

1.  Evidence for a protective role for the rs805305 single nucleotide polymorphism of dimethylarginine dimethylaminohydrolase 2 (DDAH2) in septic shock through the regulation of DDAH activity.

Authors:  Simon Lambden; James Tomlinson; Sophie Piper; Anthony C Gordon; James Leiper
Journal:  Crit Care       Date:  2018-12-11       Impact factor: 9.097

2.  DDAH2 alleviates myocardial fibrosis in diabetic cardiomyopathy through activation of the DDAH/ADMA/NOS/NO pathway in rats.

Authors:  Zhen-Dong Zhu; Ji-Ming Ye; Xue-Mei Fu; Xue-Chang Wang; Ji-Yun Ye; Xin-Ran Wu; Peng Hua; Yu-Qiong Liao; Wei Xuan; Jin-Lan Duan; Wei-Yuan Li; Hui Fu; Zhong-Hua Xia; Xuan Zhang
Journal:  Int J Mol Med       Date:  2018-12-18       Impact factor: 4.101

3.  Association of Variability in the DDAH1, DDAH2, AGXT2 and PRMT1 Genes with Circulating ADMA Concentration in Human Whole Blood.

Authors:  Juliane Hannemann; Julia Zummack; Jonas Hillig; Leonard Rendant-Gantzberg; Rainer Böger
Journal:  J Clin Med       Date:  2022-02-11       Impact factor: 4.241

4.  Hypermethylation of DDAH2 promoter contributes to the dysfunction of endothelial progenitor cells in coronary artery disease patients.

Authors:  Pan-Pan Niu; Yu Cao; Ting Gong; Jin-Hui Guo; Bi-Kui Zhang; Su-Jie Jia
Journal:  J Transl Med       Date:  2014-06-16       Impact factor: 5.531

5.  Dimethylarginine Dimethylaminohydrolase 2 (DDAH 2) Gene Polymorphism, Asymmetric Dimethylarginine (ADMA) Concentrations, and Risk of Coronary Artery Disease: A Case-Control Study.

Authors:  Chao Xuan; Long-Qiang Xu; Qing-Wu Tian; Hui Li; Qing Wang; Guo-Wei He; Li-Min Lun
Journal:  Sci Rep       Date:  2016-09-28       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.